Update: this study is closed to enrollment.
Previous expericence with antibody therapy in both non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) suggests the need for further exploration of new antibody treatments for these diseases.
This is a Phase I, open-label study being conducted in patients with recurrent non-Hodgkin’s lymphoma or chronic lymphocytic leukemia who have progressed after at least one prior standard treatment.
Click here to for the clinical and research profile of John Leonard, MD, the physician leading the study.
New Developments in Lymphoma 